Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This compound is a synthetic small molecule belonging to the class of aryl-phenylketones. It features an imidazo[1,2-a]pyridine core substituted with amino and difluorobenzoyl groups. The drug has been identified as an experimental agent and is not approved for clinical use. Its primary known biological activity is as a cyclin-dependent kinase 2 (CDK2) inhibitor in humans; however, its pharmacological action remains uncharacterized in terms of therapeutic application or efficacy. There are no marketed formulations or brand names associated with this compound at present. The molecular formula is C21H13F2N3O2 and it has been referenced under DrugBank Accession Number DB04006[1].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [2-Amino-6-(2,6-Difluoro-Benzoyl)-Imidazo[1,2-a]Pyridin-3-Yl]-Phenyl-Methanone.